siRNA Complement Factor B Inhibition via GalNAc Delivery
Solution Overview
Problem
Inappropriate or excessive complement activation leads to various serious diseases and conditions, and current complement inhibitors have limitations in effectively managing these disorders.
Innovation Solution
The use of specific siRNA molecules comprising an antisense strand and a sense strand, where the antisense strand is complementary to nucleotide sequences of complement factor B, to reduce or inhibit complement factor B expression in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current complement inhibitors are used to treat complement-mediated disorders, then complement activation is partially inhibited, but the inhibition is insufficient to effectively manage serious diseases and conditions
Solution Approach 1:
The patent changes the molecular parameter from conventional complement inhibitors to siRNA molecules, which enable more effective and specific inhibition of complement factor B. The siRNA molecules achieve up to 90% reduction in factor B transcript or protein levels, representing a significant parameter change in inhibition effectiveness compared to current therapies.
2Reliability
If siRNA molecules are used to inhibit complement factor B expression, then factor B levels are reduced by up to 90%, but the complexity of siRNA design and delivery increases
Solution Approach 1:
The patent uses GalNAc ligands as intermediaries to facilitate siRNA delivery to hepatocytes. The GalNAc moiety acts as a mediator that binds to asialoglycoprotein receptors on liver cells, enabling efficient uptake of the siRNA molecule and subsequent inhibition of complement factor B expression without requiring complex delivery systems.
3Measurement precision
If the antisense strand is made highly complementary to factor B nucleotide sequences, then inhibition specificity increases, but the risk of off-target effects and immunogenicity increases
Solution Approach 1:
The patent applies local quality modifications by introducing specific nucleotide variations and overhang regions at particular positions within the siRNA sequence. The antisense strand is designed with 19-21 nucleotides of complementarity to factor B mRNA, with 2-nucleotide 3′ overhangs that are not complementary to the target sequence. This localized modification maintains high binding affinity and specificity while reducing off-target effects and immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of these siRNA molecules effectively reduces the levels of factor B transcript or protein by up to 90%, providing a therapeutic approach to manage complement-mediated disorders.
Implementation Method 1
the antisense strand is complementary to a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 76-99
Implementation Method 2
The administration of these siRNA molecules effectively reduces the levels of factor B transcript or protein by up to 90%
Data Source
AI summary
RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.